Algorae Pharmaceuticals (ASX: 1AI) has executed a partnership with Indian company Cadila Pharmaceuticals for the commercialisation of two generic medicines to treat cardiovascular and metabolic disorders in the Australia and New Zealand markets.
Under the terms of a definitive licence and supply agreement, Cadila will be responsible for product development and manufacture, while Algorae subsidiary AlgoraeRx will hold Therapeutic Goods Administration (TGA) sponsorship, manage regulatory submissions, and oversee marketing activities across the region.
Cadila is one of India’s largest private pharmaceutical companies with vertically integrated operations across active pharmaceutical ingredients, finished formulations, contract research, and manufacturing services.
The company’s products are marketed in over 100 countries across Asia, Africa, Europe, and the Americas and its research and development division comprises over 350 scientists working across key therapeutic areas such as respiratory, cardiometabolic, gastrointestinal, oncology, anti-infective, and pain management.
Algorae said it would commence TGA registration planning and documentation for Cadila cardiovascular and metabolic medicines and would update shareholders on submission timing, anticipated launch windows and expected revenue contributions as the program advances.
Existing Licensing Agreements
The Cadila partnership complements Algorae’s existing licencing agreement with Sakar Healthcare for the launch of five generic oncology medicines in Australia and New Zealand.
The company also has a distribution agreement in place with ++Dr Reddy’s Laboratories++ to supply chemotherapy medicine Capecitabine 500mg to the Australian market.
Collectively, these deals establish a multi-partner, multi-therapy commercial platform spanning oncology, cardiovascular, and metabolic diseases targeting hospitals, pharmacies, and other institutional customers.
They align with Algorae’s ongoing research and development activities in the oncology sector at the prestigious ++Peter MacCallum Cancer Centre++ in Melbourne.
AlgoraeOS v1 and v2 Validation
The centre has been integral to the independent pre-clinical validation of the AlgoraeOS Version 1 drug-combination prediction platform and the ++newly-launched Version 2 upgrade++.
The new version incorporates confidence-weighted predictions and full dose-response modelling across multiple synergy metrics.
Validation generated approximately 10,000 data points across 84 cannabidiol-drug-cell line combinations, confirming the platform’s ability to prioritise combinations with true biological synergy.
Independent validation of Version 2 aims to further de-risk the platform while narrowing the pipeline toward combinations with the strongest translational potential.
